Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGOBSERVATIONAL

The Norwegian Antirheumatic Drug Register

Long-term Safety and Effectiveness of Disease Modifying Therapies in Inflammatory Arthropathies: a Multicentre, Phase IV, Longitudinal Observational Study

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

NOR-DMARD is a register-based longitudinal observational study of which the main objectives are to study the effectiveness of treatment of inflammatory joint diseases with biological disease modifying anti-rheumatic drugs (DMARDs) in clinical practice, by measuring disease activity, health related quality of life, function and joint damage, and to study the long-term safety of such treatment. Other objectives include the assessment of cost-effectiveness of treatment, to identify and and validate clinical, genetic and immunological predictors of efficacy and adverse events, to assess the impact of treatment with biological DMARDs on work participation and work productivity, to investigate different strategies for use of biological DMARDs, to assess the performance of different outcome measures, and to ensure a systematic and timely follow-up of patients treated with biological DMARDs.

Who May Be Eligible (Plain English)

Who May Qualify: - Age \>18 years - Diagnosis of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, spondyloarthritis, adult juvenile idiopathic arthritis, undifferentiated arthritis, or any other inflammatory arthritis - Clinical indication to start a new treatment with a biological disease modifying anti-rheumatic drug or a kinase inhibitor Who Should NOT Join This Trial: - Unwillingness or unability to give written willing to sign a consent form - Psychiatric or mental disorders, alcohol abuse or other abuse of substances, language barriers or other factors which makes adherence to the study protocol impossible - Participation in blinded RCTs or other studies incompatible with the NOR-DMARD study protocol Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Age \>18 years * Diagnosis of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, spondyloarthritis, adult juvenile idiopathic arthritis, undifferentiated arthritis, or any other inflammatory arthritis * Clinical indication to start a new treatment with a biological disease modifying anti-rheumatic drug or a kinase inhibitor Exclusion Criteria: * Unwillingness or unability to give written informed consent * Psychiatric or mental disorders, alcohol abuse or other abuse of substances, language barriers or other factors which makes adherence to the study protocol impossible * Participation in blinded RCTs or other studies incompatible with the NOR-DMARD study protocol

Locations (6)

Vestre Viken HF Drammen Hospital
Drammen, Buskerud, Norway
Lillehammer Hospital for Rheumatic Diseases
Lillehammer, Oppland, Norway
Førde Hospital
Førde, Sogn Og Fjordane, Norway
St. Olavs Hospital
Trondheim, Sør-Trøndelag, Norway
University Hospital of Northern Norway
Tromsø, Troms, Norway
Diakonhjemmet Hospital
Oslo, Norway